CN108358865A - 一种新型的多取代噻唑类化合物的制备方法 - Google Patents
一种新型的多取代噻唑类化合物的制备方法 Download PDFInfo
- Publication number
- CN108358865A CN108358865A CN201810192510.1A CN201810192510A CN108358865A CN 108358865 A CN108358865 A CN 108358865A CN 201810192510 A CN201810192510 A CN 201810192510A CN 108358865 A CN108358865 A CN 108358865A
- Authority
- CN
- China
- Prior art keywords
- preparation
- sulphur
- reaction
- cdcl
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 polysubstituted thiazole compound Chemical class 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000005864 Sulphur Substances 0.000 claims abstract description 22
- 238000006243 chemical reaction Methods 0.000 claims abstract description 21
- 239000003054 catalyst Substances 0.000 claims abstract description 7
- 239000002904 solvent Substances 0.000 claims abstract description 7
- 150000002081 enamines Chemical class 0.000 claims abstract description 6
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical class CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 13
- 150000002466 imines Chemical class 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 230000000269 nucleophilic effect Effects 0.000 claims description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 3
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 claims description 3
- 230000001590 oxidative effect Effects 0.000 claims description 3
- 239000012266 salt solution Substances 0.000 claims description 3
- 229920006395 saturated elastomer Chemical class 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- 150000003557 thiazoles Chemical class 0.000 claims description 3
- 238000004809 thin layer chromatography Methods 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 229910021575 Iron(II) bromide Inorganic materials 0.000 claims 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 1
- 229940046149 ferrous bromide Drugs 0.000 claims 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 claims 1
- GYCHYNMREWYSKH-UHFFFAOYSA-L iron(ii) bromide Chemical compound [Fe+2].[Br-].[Br-] GYCHYNMREWYSKH-UHFFFAOYSA-L 0.000 claims 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 claims 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 12
- 239000002994 raw material Substances 0.000 abstract description 11
- 239000000758 substrate Substances 0.000 abstract description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 104
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 description 26
- 238000001819 mass spectrum Methods 0.000 description 26
- 230000005311 nuclear magnetism Effects 0.000 description 26
- 239000000047 product Substances 0.000 description 26
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 6
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- 150000004982 aromatic amines Chemical class 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- IAXLQZFJGQNGBQ-SCSAIBSYSA-N (2s)-2-amino-4-hydroxy-3,3-dimethylbutanoic acid Chemical compound OCC(C)(C)[C@H](N)C(O)=O IAXLQZFJGQNGBQ-SCSAIBSYSA-N 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000005899 aromatization reaction Methods 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- 0 *C(c1c(-c2ccccc2)nc(-c(cc2)ccc2Br)[s]1)=O Chemical compound *C(c1c(-c2ccccc2)nc(-c(cc2)ccc2Br)[s]1)=O 0.000 description 1
- YXWWUNNKMJZIOW-UHFFFAOYSA-N 2-ethyl-5-methyl-1,3-thiazole Chemical class CCC1=NC=C(C)S1 YXWWUNNKMJZIOW-UHFFFAOYSA-N 0.000 description 1
- XBHOUXSGHYZCNH-UHFFFAOYSA-N 2-phenyl-1,3-benzothiazole Chemical class C1=CC=CC=C1C1=NC2=CC=CC=C2S1 XBHOUXSGHYZCNH-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- VKJZQZMHVDSUMP-GKINTKIXSA-N CCC/C(/C)=N/C(/c1ccccc1)=C(/C(c1ccccc1)=O)\S Chemical compound CCC/C(/C)=N/C(/c1ccccc1)=C(/C(c1ccccc1)=O)\S VKJZQZMHVDSUMP-GKINTKIXSA-N 0.000 description 1
- FDCGVHNWOOTHLV-UHFFFAOYSA-N CN(C)c(cc1)ccc1C(c1c(-c2ccccc2)nc(-c2ccccc2)[s]1)=O Chemical compound CN(C)c(cc1)ccc1C(c1c(-c2ccccc2)nc(-c2ccccc2)[s]1)=O FDCGVHNWOOTHLV-UHFFFAOYSA-N 0.000 description 1
- ZSMXXYNJNNEYLC-UHFFFAOYSA-N COc(cc1)ccc1C(c1c(-c2ccccc2)nc(-c2ccccc2)[s]1)=O Chemical compound COc(cc1)ccc1C(c1c(-c2ccccc2)nc(-c2ccccc2)[s]1)=O ZSMXXYNJNNEYLC-UHFFFAOYSA-N 0.000 description 1
- CZWJVCRQXLQDOV-UHFFFAOYSA-N O=C(c1c(-c2ccccc2)nc(-c2ccc(cccc3)c3c2)[s]1)c1ccccc1 Chemical compound O=C(c1c(-c2ccccc2)nc(-c2ccc(cccc3)c3c2)[s]1)c1ccccc1 CZWJVCRQXLQDOV-UHFFFAOYSA-N 0.000 description 1
- CENBVYMITMLZLE-UHFFFAOYSA-N O=C(c1c(-c2ccccc2)nc(C(F)F)[s]1)c1ccccc1 Chemical compound O=C(c1c(-c2ccccc2)nc(C(F)F)[s]1)c1ccccc1 CENBVYMITMLZLE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940125890 compound Ia Drugs 0.000 description 1
- 238000006477 desulfuration reaction Methods 0.000 description 1
- 230000023556 desulfurization Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
本发明提供了一种新型的利用烯胺和硫磺为原料在空气条件下合成多取代的噻唑类化合物的方法。本发明在以无水三氯化铁为催化剂和二甲基亚砜为溶剂的反应体系下简单直接合成了多取代的噻唑类化合物。该反应是首次利用烯胺和硫磺为底物合成多取代的噻唑类化合物，且硫磺为硫原子的供体，反应步骤少，反应对空气不敏感。同时本发明还具有反应条件简单，廉价，操作安全，收率高等特点，具有极大的工业化应用价值。
Description
技术领域
本发明属于有机合成技术领域，具体涉及一种多取代噻唑化合物的制备方法。
背景技术
多取代噻唑是一类重要的化合物，该类化合物不仅是许多天然产物的核心结构单元，而且在生物、医药等领域有着广泛的应用。例如，抗疟疾药物，抗HIV药物，抗癌药物等中都含有多取代噻唑骨架。因此多取代噻唑化合物合成的方法学研究一直被人们所关注。
近年来多取代噻唑化合物的合成方法取得了较好的进展。列举如下：
(1)以α-对甲苯磺酰氧基酮、炔基碘鎓和硫脲为底物：
Hideo Togo1a和Srikanth Venkatraman1b小组分别以α-对甲苯磺酰氧基酮、炔基碘鎓和硫脲为反应底物，在碱性环境下反应均可生成取代基噻唑。
(2)以α-氨基-β-酮酯和Lawesson's试剂为底物：
Santos Fustero小组发现α-氨基-β-酮酯和Lawesson's试剂为原料，在四氢呋喃溶液中回流，一段时间后通过TCL检测可获得取代基的噻唑。2
(3)以三(1-丙烯基)胺和硫磺为底物：
G.K.Musorin小组发现以三(1-丙烯基)胺和硫磺为原料，在DMF或者DMSO中加热至50℃，通过分子内的环化反应生成5-甲基-2-乙基噻唑。3
(4)以烯胺和亚硫酰氯为底物：
Kanchugarakoppal S.Rangappa小组以烯胺和亚硫酰氯为原料，在DMAP的作用下，烯胺酮通过对亚硫酰氯的亲核进攻，随后经过HCl的消除、去质子化、分子内环化及脱氧一系列过程，最终合成多取代的噻唑化合物。4
(4)以N-苄基芳胺和硫磺为底物：
Guobo Deng小组以N-苄基芳胺和硫磺为原料，DMSO为氧化剂，氧化N-苄基芳胺为亚胺，随后经过硫的亲电、亲核进攻、分子内的环化和氧化芳构化一系列的过程，最终生成2-苯基苯并噻唑。5
(5)以芳基胺、苯甲醛和硫磺为底物：
Guo-Jun Deng小组以芳基胺、苯甲醛和硫磺为原料，KI为催化剂，芳基胺与苯甲醛首先通过脱水缩合形成亚胺，随后经历硫对亚胺的亲电进攻、脱硫、去质子化、亲核环化及氧化芳构化一系列过程，最终合成苯并噻唑。另外一种反应路径是由硫对亚胺的亲核开始的一系列过程。6
(6)以芳基醛、腈基胺和硫磺为底物：
Eric Romeo小组以芳基醛、腈基胺和硫磺为原料，在碱性环境下，芳基醛与腈基胺先进性脱水缩合形成亚胺，亚胺随后经历互变异构、硫的亲电进攻、环化、互变异构一系列过程，最后形成取代基的噻唑。7
以上几种方法的缺点是原料制备方法复杂，反应条件苛刻，原料不稳定，反应成本较高，无法实现工业化应用，其次至今没有提供很好的能够简单合成取代基的噻唑的制备方法。
本发明所要解决的技术问题在于提供简单高效全新的多取代噻唑化合物的制备方法。
为解决上述技术问题，本发明采用的技术方案是：一种新型的多取代噻唑化合物的制备方法，包括以下步骤：在反应器中加入具有通式I和硫磺的化合物，溶剂二甲基亚砜(DMSO)，催化剂为无水三氯化铁，空气中在140℃的油浴锅中反应7.0h，薄层色谱监测反应进程，直至反应完全；用乙酸乙酯和饱和食盐水萃取，用无水硫酸钠干燥，减压蒸出溶剂，后用石油醚/乙酸乙酯＝40/1的流动相经硅胶柱层析分离纯化，得到化合物III，反应方程式如下：
方程式中：R1为芳基、烷基，R2为芳基、烷基，R3为芳基、烷基、烷氧基。
上述的这种多取代噻唑化合物的制备方法，其特征在于，原料廉价易得且在空气环境下反应，在催化氧化条件下使烯胺氧化为亚胺，随后硫对亚胺中间体进行亲电或者亲核两种方式进攻，最终通过分子内环化氧化得到最终产物。
本发明与现有技术相比具有以下优点：
1、本发明所用原料廉价易得，在空气环境下反应，操作简便，底物兼容性好，产率高等优点。
2、本发明使用硫磺为硫原子的供体进行噻唑的构建，整个反应过程包括了氧化环化的过程。
3、本发明不需要昂贵的催化剂且操作较安全。
下面通过实施例，对本发明技术方案做进一步的详细说明。具体实施方式
实施例1：本实施例的制备方法包括以下步骤：
在反应管中依次加入化合物Ia(0.30mmol)、硫磺(0.9mmol)、DMSO(2mL)、FeCl3(0.03mmol)，放在140℃的油浴锅中，反应7.0h，薄层色谱监测反应进程，直至反应完全；用乙酸乙酯和饱和食盐水萃取，用无水硫酸钠干燥，减压蒸出溶剂，残渣用石油醚/乙酸乙酯＝40/1的流动相经硅胶柱层析分离纯化，得到化合物IIIa，收率99％。反应方程式如下：
实施例1所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝8.08-8.06(m,2H),7.70-7.67(m,2H),7.54-7.52(m,2H),7.49-7.45(m,3H),7.40-7.35(m,1H),7.24-7.18(m,5H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.6,170.1,158.8,137.2,134.3,133.0,132.9,131.5,131.3,129.9,129.8,129.2,128.9,128.2,128.1,127.1；HRMS calcd for C22H16NOS[M+H]+342.0947；found:342.0946.
实施例2所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝7.89-7.87(m,1H),7.74-7.71(m,2H),7.56-7.53(m,2H),7.42-7.28(m,4H),7.26-7.17(m,5H),2.72(s,3H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.8,169.9,157.9,137.2,137.1,134.3,133.1,132.2,131.9,131.8,130.4,130.2,129.9,129.8,128.9,128.3,128.2,126.5,22.0；HRMS calcd for C23H18NOS[M+H]+356.1104；found:356.1100.
实施例3所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝7.92(s,1H),7.87-7.85(d,J＝7.6Hz,1H),7.70-7.68(d,J＝8.0Hz,2H),7.54-7.52(m,2H),7.41-7.30(m,3H),7.25-7.19(m,5H),2.44(s,3H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.6,170.4,158.8,139.1,137.3,134.4,133.0,132.9,132.1,131.4,129.9,129.8,129.1,128.9,128.2,128.1,127.6,124.3,21.5；HRMScalcd for C23H18NOS[M+H]+356.1104；found:356.1110.
实施例4所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝7.98-7.96(d,J＝8.0Hz,2H),7.69-7.67(d,J＝8.0Hz,2H),7.53-7.51(m,2H),7.40-7.36(m,1H),7.29-7.18(m,7H),2.42(s,3H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.6,170.4,158.9,141.8,137.3,134.4,132.9,131.1,130.4,130.0,129.9,129.8,128.9,128.2,128.1,127.0,21.7；HRMS calcd for C23H18NOS[M+H]+356.1104；found:356.1101.
实施例5所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝7.69-7.67(m,2H),7.64-7.60(m,2H),7.54-7.52(m,2H),7.39-7.35(m,2H),7.24-7.18(m,5H),7.04-7.01(m,1H),3.87(s,3H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.5,169.9,160.2,158.7,137.2,134.3,134.2,133.1,131.6,130.3,129.9,129.8,129.0,128.3,128.2,119.7,117.5,111.7,55.6；HRMS calcd forC23H18NO2S[M+H]+372.1053；found:372.1045.
实施例6所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝7.69-7.67(m,2H),7.54-7.52(m,2H),7.39-7.36(m,1H),7.25-7.16(m,7H),6.59-6.58(m,1H),3.85(s,6H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.5,169.9,161.3,158.7,137.2,134.7,134.3,133.1,131.6,129.9,129.8,129.0,128.3,128.1,104.9,103.6,55.7；HRMS calcd for C24H20NO3S[M+H]+402.1159；found:402.1152.
实施例7所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝8.49-8.44(m,1H),7.71-7.70(m,2H),7.57-7.54(m,2H),7.48-7.38(m,2H),7.31-7.19(m,7H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.7,162.2-162.1(d,J＝5.0Hz,1C),161.8-159.3(d,J＝252.0Hz,1C),157.5,137.3,134.2,133.1,132.4,132.3,129.9,129.8,129.2,129.0,128.3,128.2,124.9-124.8(d,J＝3.0Hz,1C),121.0-120.9(d,J＝11.0Hz,1C),116.5-116.3(d,J＝22.0Hz,1C)；HRMS calcd forC22H15FNOS[M+H]+360.0853；found:360.0848.
实施例8所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝7.84-7.79(m,2H),7.70-7.67(m,2H),7.54-7.51(m,2H),7.46-7.37(m,2H),7.24-7.15(m,6H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.4,168.4-168.3(d,J＝3.0Hz,1C),164.4-161.9(d,J＝246.0Hz,1C),158.7,137.0,135.0-134.9(d,J＝8.0Hz,1C),134.1,133.2,132.0,130.9-130.8(d,J＝8.0Hz,1C),129.8,129.1,128.3,128.2,122.9-122.8(d,J＝3.0Hz,1C),118.2-118.0(d,J＝22.0Hz,1C),114.0,113.7；HRMS calcd for C22H15FNOS[M+H]+360.0853；found:360.0859.
实施例9所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝8.08-8.05(m,2H),7.69-7.67(d,J＝7.6Hz,2H),7.52-7.50(m,2H),7.40-7.36(m,1H),7.25-7.14(m,7H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.5,168.8,165.9-163.4(d,J＝251.0Hz,1C),158.8,137.1,134.2,133.1,131.6,129.8-129.8(d,J＝3.0Hz,1C),129.4,129.3,129.2,129.1,129.0,128.3-128.2(d,J＝8.0Hz,1C),116.5-116.3(d,J＝22.0Hz,1C)；HRMS calcd for C22H15FNOS[M+H]+360.0853；found:360.0856.
实施例10所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝8.01-7.98(m,2H),7.69-7.67(m,2H),7.52-7.50(m,2H),7.46-7.42(m,2H),7.40-7.36(m,1H),7.25-7.18(m,5H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.4,168.6,158.8,137.3,137.1,134.1,133.1,131.8,131.5,129.8,129.5,129.1,128.3,128.2；HRMS calcd for C22H15ClNOS[M+H]+376.0558；found:376.0566.
实施例11所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝8.47-8.45(d,J＝8.8Hz,1H),7.72-7.70(m,2H),7.55-7.53(m,3H),7.43-7.38(m,2H),7.27-7.20(m,5H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.6,163.8,157.1,137.1,136.8,134.0,133.3,133.1,132.9,131.9,130.6,130.0129.9,129.8,129.0,128.3,128.2,127.8；HRMS calcd for C22H14Cl2NOS[M+H]+410.0168；found:410.0172.
实施例12所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝7.95-7.92(m,2H),7.69-7.67(m,2H),7.62-7.60(m,2H),7.52-7.50(m,2H),7.41-7.37(m,1H),7.25-7.19(m,5H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.4,168.7,158.8,137.1,134.1,133.1,132.4,131.9,131.8,129.8,129.1,128.4,128.3,128.2,125.7；HRMS calcd for C22H15BrNOS[M+H]+420.0052；found:420.0060.
实施例13所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝7.66-7.64(m,2H),7.44-7.42(m,2H),7.39-7.35(m,1H),7.23-7.13(m,5H),3.09-3.05(m,2H),1.96-1.87(m,2H),1.11-1.07(m,3H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.7,174.5,157.7,137.2,134.3,132.9,131.1,129.8,129.7,128.7,128.2,128.1,35.9,23.5,13.9；HRMS calcd for C19H18NOS[M+H]+308.1104；found:308.1109.
实施例14所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝7.66-7.63(m,2H),7.44-7.42(m,2H),7.39-7.35(m,1H),7.23-7.14(m,5H),3.10-3.06(m,2H),1.96-1.84(m,2H),1.50-1.43(m,2H),1.39-1.25(m,6H),0.91-0.88(m,3H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.6,174.8,157.7,137.1,134.2,132.8,131.0,129.7,129.6,128.7,128.1,128.0,33.9,31.7,30.1,29.2,29.0,22.7,14.2；HRMS calcd for C23H26NOS[M+H]+364.1730；found:364.1726.
实施例15所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝7.65-7.63(m,2H),7.44-7.42(m,2H),7.38-7.34(m,1H),7.22-7.12(m,5H),3.09-3.06(m,2H),1.91-1.83(m,2H),1.48-1.43(m,2H),1.26(s,26H),0.89-0.86(m,3H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.7,174.8,157.7,137.2,134.3,132.9,131.0,129.8,129.7,128.7,128.2,128.1,34.0,32.0,30.1,29.8,29.7,29.7,29.6,29.5 29.4,29.3,22.8,14.3；HRMS calcd for C33H46NOS[M+H]+504.3295；found:504.3302.
实施例16所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝7.69-7.67(m,2H),7.48-7.41(m,3H),7.27-7.19(m,5H),7.05-6.77(m,1H)；13C NMR(100MHz,CDCl3,ppm):δ＝190.0,163.3-162.7(t,J＝30.0Hz,1C),157.5,136.3,133.8,133.5,133.2,129.9,129.6,129.4,128.5,128.4,113.0-108.2(t,J＝239.0Hz,1C)；HRMS calcd for C17H12F2NOS[M+H]+316.0602；found:316.0606.
实施例17所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝7.66-7.64(m,2H),7.59-7.58(d,J＝1.2Hz,1H),7.49-7.47(m,2H),7.39-7.36(m,1H),7.23-7.17(m,6H),6.60-6.58(m,1H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.3,159.9,159.1,148.6,144.9,137.2,134.1,132.9,130.9,129.8,129.7,129.0,128.2,128.1,112.8,111.3；HRMS calcd for C20H14NO2S[M+H]+332.0740；found:332.0737.
实施例18所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝9.00-8.98(d,J＝8.4Hz,1H),7.99-7.91(m,3H),7.78-7.76(m,2H),7.65-7.52(m,5H),7.43-7.39(m,1H),7.28-7.21(m,5H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.7,169.8,158.3,137.2,134.3,134.2,133.2,132.0,131.6,130.5,130.0,129.9,129.8,129.2,129.0,128.7,128.3,128.2,127.9,126.7,125.9,125.2；HRMS calcd for C26H18NOS[M+H]+392.1104；found:392.1110.
实施例19所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝8.62-8.60(m,2H),7.79-7.77(m,2H),7.69-7.65(m,1H),7.61-7.53(m,4H),7.51-7.47(m,1H),7.34-7.25(m,5H)；13C NMR(100MHz,CDCl3,ppm):δ＝189.5,183.8,167.9,157.9,136.5,136.5,134.7,134.2,134.0,133.6,131.5,130.0,129.4,129.3,128.7,128.6,128.5；HRMS calcd for C23H16NO2S[M+H]+370.0896；found:370.0891.
实施例20所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝8.01-7.98(m,2H),7.87-7.84(m,2H),7.63-7.59(m,1H),7.53-7.43(m,5H),2.68(s,3H)；13C NMR(100MHz,CDCl3,ppm):δ＝188.8,170.4,160.6,139.8,132.9,132.8,131.3,129.7,129.2,129.0,128.6,127.0,18.7；HRMS calcdfor C17H14NOS[M+H]+280.0791；found:280.0788.
实施例21所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝8.00-7.98(m,2H),7.92-7.88(m,2H),7.49-7.44(m,3H),7.21-7.16(m,2H),2.67(s,3H)；13C NMR(100MHz,CDCl3,ppm):δ＝187.2,170.3,166.7-164.2(d,J＝253.0Hz,1C),160.5,135.9-135.8(d,J＝3.0Hz,1C),132.7,131.6-131.5(d,J＝9.0Hz,1C),131.3,129.2,129.1,126.9,115.9-115.6(d,J＝22.0Hz,1C),18.6；HRMS calcd for C17H13FNOS[M+H]+298.0697；found:298.0693.
实施例22所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝8.05-8.03(m,2H),7.84-7.82(m,2H),7.48-7.43(m,6H),4.32-4.27(m,2H),1.32-1.29(m,3H)；13C NMR(100MHz,CDCl3,ppm):δ＝169.9,161.7,160.9,134.3,133.0,131.2,130.0,129.3,129.2,127.9,127.0,122.5,61.6,14.3；HRMS calcd for C18H16NO2S[M+H]+310.0896；found:310.0891.
实施例23所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝8.08-8.05(m,2H),7.53-7.47(m,7H),7.35-7.33(d,J＝8.4Hz,2H),7.25-7.19(m,3H)；13C NMR(100MHz,CDCl3,ppm):δ＝188.5,170.5,159.0,135.9,134.1,132.9,131.5,131.4,131.3,131.2,129.9,129.3,129.2,128.3,128.1,127.1；HRMS calcd for C22H15BrNOS[M+H]+420.0052；found:420.0041.
实施例24所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝8.08-8.05(m,2H),7.74-7.72(d,J＝8.8Hz,2H),7.60-7.58(m,2H),7.49-7.47(m,3H),7.25-7.22(m,3H),6.74-6.72(d,J＝9.2Hz,2H),3.77(s,3H)；13C NMR(100MHz,CDCl3,ppm):δ＝188.0,169.2,163.6,157.6,134.3,133.0,132.4,131.2,131.0,129.8,129.6,129.1,128.8,128.2,126.9,113.5,55.5；HRMS calcd forC23H18NO2S[M+H]+372.1053；found:372.1058.
实施例25所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝8.06-8.04(m,2H),7.74-7.68(m,4H),7.47-7.46(m,3H),7.28-7.23(m,3H),6.49-6.47(d,J＝9.2Hz,2H),2.99(s,6H)；13C NMR(100MHz,CDCl3,ppm):δ＝187.1,167.9,155.9,153.7,134.5,133.2,132.6,131.3,130.7,129.3,129.1,128.5,128.2,126.8,124.4,110.5,40.0；HRMS calcd for C24H21N2OS[M+H]+385.1369；found:385.1362.
实施例26所得产品的结构、核磁、高分辨质谱数据如下：
1H NMR(400MHz,CDCl3,ppm):δ＝8.22-8.20(m,2H),8.02-7.99(m,2H),7.54-7.46(m,6H)；13C NMR(100MHz,CDCl3,ppm):δ＝171.4,163.4,132.3,132.1,132.0,130.6,129.4,129.1,128.2,127.3,113.9,98.1；HRMS calcd for C16H11N2S[M+H]+263.0638；found:263.0636.
参考文献：
1.a)M.Ueno and H.Togo,Synthesis.,2004,16,2673.b)P.Wipf,S.Venkatraman,J.Org.Chem.,1996,61,8004.
2.J.F.Sanz-Cervera,R.Blasco,J.Piera,M.Cynamon,M. and S.FusteroJ.Org.Chem.2009,74,8988.
3.G.K.Musorin and J.Gen.Russ.Chem.,2002,72,325.
4.T.R.Swaroop,H.Ila and K.S.Rangappa,Tetrahedron Lett.,2013,54,5288.
5.X.M.Zhu,Y.Z.Yang,G.H.Xiao,J.X.Song,Y.Liang and G.B.Deng,Chem.Commun.,2017,53,11917
6.X.-Z.Che,J.J.Jiang,F.H.Xiao,H.W.Huang and G.J.Deng,Org.Lett.,2017,19,4576.
7.K.K.Childers,A.M.Haidle,M.R.Machacek,J.P.Rogers,E.Romeo,TetrahedronLett.2013,54,2506.
Claims (5)
1.一种新型的多取代噻唑的制备方法，包括以下步骤：在反应器中加入具有通式I和II的化合物，溶剂二甲基亚砜(DMSO)，催化剂为无水三氯化铁，空气条件下在140℃的油浴锅中反应7.0h，薄层色谱监测反应进程，直至反应完全；用乙酸乙酯和饱和食盐水萃取，用无水硫酸钠干燥，减压蒸出溶剂，残渣用石油醚/乙酸乙酯＝40/1的流动相经硅胶柱层析分离纯化，得到化合物III，反应方程式如下：
方程式中：R1选自芳基、烷基，R2选自芳基、烷基，R3选自芳基、烷基、烷氧基。上述的一种新型的的多取代噻唑制备方法，其特征在于，用随处可见的空气和硫磺作为氧化剂，在催化氧化条件下使烯胺氧化为亚胺，随后硫对亚胺中间体进行亲电或者亲核两种方式进攻，最终通过分子内环化氧化得到最终产物。
2.根据权利要求1所述的一种新型的的多取代噻唑类化合物的制备方法，其特征在于，所述催化剂为碘，氯化亚铁，无水三氯化铁，六水合三氯化铁，溴化亚铁。
3.根据权利要求1所述的一种新型的的多取代噻唑类化合物的制备方法，其特征在于，所述溶剂为N-甲基吡咯烷酮，二甲基亚砜，N，N-二甲基乙酰胺，N，N-二甲基甲酰胺，环丁砜，六甲基磷酰三胺。
4.根据权利要求1所述的一种新型的的多取代噻唑类化合物的制备方法，其特征在于，所述通式化合物I和硫磺以及催化剂的用量的摩尔比为1:2.0-5.0: 0.1-0.5。
5.根据权利要求1所述的一种新型的的多取代噻唑类化合物的制备方法，其特征在于，所述反应温度为80-160℃。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810192510.1A CN108358865B (zh) | 2018-03-08 | 2018-03-08 | 一种多取代噻唑类化合物的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810192510.1A CN108358865B (zh) | 2018-03-08 | 2018-03-08 | 一种多取代噻唑类化合物的制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108358865A true CN108358865A (zh) | 2018-08-03 |
| CN108358865B CN108358865B (zh) | 2021-07-27 |
Family
ID=63003618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810192510.1A Expired - Fee Related CN108358865B (zh) | 2018-03-08 | 2018-03-08 | 一种多取代噻唑类化合物的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108358865B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112321583A (zh) * | 2020-12-02 | 2021-02-05 | 安徽理工大学 | 一种1,2,4-噻二唑化合物的合成方法 |
| CN112679447A (zh) * | 2021-01-05 | 2021-04-20 | 兰州大学 | 一种多取代噻唑-2(3h)-酮化合物的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3244703A (en) * | 1961-10-19 | 1966-04-05 | Shell Oil Co | Thiazine, thiazoline, and thiazolinone compounds |
| CN105859651A (zh) * | 2016-04-13 | 2016-08-17 | 华东师范大学 | 噻唑类衍生物及其合成方法和应用 |
-
2018
- 2018-03-08 CN CN201810192510.1A patent/CN108358865B/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3244703A (en) * | 1961-10-19 | 1966-04-05 | Shell Oil Co | Thiazine, thiazoline, and thiazolinone compounds |
| CN105859651A (zh) * | 2016-04-13 | 2016-08-17 | 华东师范大学 | 噻唑类衍生物及其合成方法和应用 |
Non-Patent Citations (5)
| Title |
|---|
| DAVID S. MILLAN: ""The chemistry of 5-oxodihydroisoxazoles. Part 22.1 The synthesis of 1,3-oxazin-6-ones from N-thioacylisoxazol-5(2H )-ones"", 《J. CHEM. SOC., PERKIN TRANS. 1》 * |
| GOERDELER, JOACHIM等: ""Sulfur extrusion from 5(2H)-isothiazolones and 5(2H)-isothiazolethiones to give intermediate imidoylketenes and imidoylthioketenes"", 《CHEMISCHE BERICHTE》 * |
| K.C.MAJUMDAR: ""An efficient synthesis of coumarin- and quinolone-annulated thiazole derivatives via ligand-free iron (III)-catalyzed coupling followed by acid-promoted condensation"", 《TETRAHEDRON LETTERS》 * |
| WEN LI-RONG: ""Switching Regioselectivity of beta-Ketothioamides by Means of Iodine Catalysis: Synthesis of Thiazolylidenes and 1,4-Dithiines"", 《CHEM. EUR. J.》 * |
| 李艳丽: ""噻唑类化合物及苯并噻嗪类化合物的合成研究"", 《华东师范大学硕士学位论文》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112321583A (zh) * | 2020-12-02 | 2021-02-05 | 安徽理工大学 | 一种1,2,4-噻二唑化合物的合成方法 |
| CN112321583B (zh) * | 2020-12-02 | 2023-05-09 | 安徽理工大学 | 一种1,2,4-噻二唑化合物的合成方法 |
| CN112679447A (zh) * | 2021-01-05 | 2021-04-20 | 兰州大学 | 一种多取代噻唑-2(3h)-酮化合物的制备方法 |
| CN112679447B (zh) * | 2021-01-05 | 2022-12-06 | 甘肃森瀚石油科技有限公司 | 一种多取代噻唑-2(3h)-酮化合物的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108358865B (zh) | 2021-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Direct synthesis of α-ketothioamides from aryl methyl ketones and amines via I2-promoted sp3 C–H functionalization | |
| Fan et al. | Synthesis of heteroaryl ketones via tandem reaction of 1, 1-dibromoethenes | |
| Schuh et al. | A domino copper-catalyzed CN and CO cross-coupling for the conversion of primary amides into oxazoles | |
| Qin et al. | TBAI/TBHP catalyzed direct N-acylation of sulfoximines with aldehydes | |
| CN104610250A (zh) | 含三个氮杂环的1,2,3-噻二唑-5-甲脒类化合物及合成 | |
| CN114456117B (zh) | 一种碘促进的制备n-芳基吡唑类化合物的方法 | |
| CN105801575A (zh) | 一种咪唑并[1,2-a]吡啶的合成方法 | |
| Liao et al. | Isothiocyanation of amines using the Langlois reagent | |
| CN108358865A (zh) | 一种新型的多取代噻唑类化合物的制备方法 | |
| CN103508942A (zh) | 一种2,3-二氯-5-甲基吡啶的合成方法 | |
| CN105481752B (zh) | 一种3‑氟烯基氧化吲哚‑螺‑3,3’‑三氟甲基氧化吲哚类化合物的制备方法 | |
| CN104910098B (zh) | 一种2‑芳基苯并噻唑类化合物的合成方法 | |
| Khalaj et al. | Novel catalytic three-component reaction between a terminal alkyne, sulfonyl azide, and o-methyl oxime | |
| Ishiwata et al. | Facile preparation of thiazoles from 1H-1-(1′-alkynyl)-5-methyl-1, 2, 3-benziodoxathiole 3, 3-dioxide with thioamides | |
| CN102675223B (zh) | 一种多取代喹唑啉及杂环并嘧啶衍生物的制备方法 | |
| CN107935997A (zh) | 一种奥斯替尼的合成方法 | |
| Yang et al. | Selective syntheses of benzoxazoles and N-(2-hydroxyaryl) pyrrolidin-2-ones from the corresponding cyclopropyl amides with PPh3/CX4 | |
| Su et al. | A simple and efficient procedure for the Beckmann rearrangement of oxime using bis-(trichloromethyl) carbonate/DMF | |
| Zhi et al. | The combination of TsNBr2/TsNH2 as the nitrogen/halo source for the aminobromination of β-methyl-β-nitrostyrenes catalyzed by Mn (OAc) 2 | |
| CN109574818A (zh) | 一种多取代茚酮衍生物及其制备方法 | |
| CN109879865B (zh) | 一种2-芳基-5-(2-喹啉基)-1,3,4-噁二唑类化合物的制备方法 | |
| CN104974059B (zh) | 一种利伐沙班中间体及其制备方法 | |
| CN105153048B (zh) | 一种2,4‑喹唑啉二酮类化合物的制备方法 | |
| KR102674919B1 (ko) | 3-브로모-5-(2-에틸이미다조[1,2-a]피리딘-3-카르보닐)-2-하이드록시벤조니트릴의 합성 | |
| CN110963981B (zh) | 一类苯并噻唑芳基化合物衍生物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210727 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |